Summary
Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial responses were observed. The major toxicity was gastrointestinal. Fifty percent of patients experienced nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of liver enzymes. Mild reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent to treat recurrent epidermoid carcinoma of the head and neck.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Clarke DA, Philips FS, Steinberg SS, Barclay RK, Stock CC: Effects of N-methylformamide and related compounds in mouse sarcoma 180. Proc Soc Exp Biol 84:203–207, 1953
Furst A, Cutting WC and Gross H: Retardation of growth of Ehrlich ascites tumor by formamide and related compounds. Cancer Res 15:294–299, 1955
Myers WPL, Karnofsky DA, Burchenul JH: The hepatotoxic action of N-methylformamide in man. Cancer 9:949–954, 1956
Dexter DI, Barkosa JA and Calabresi P: N1 N-dimethylformamide induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res 39:1020–1025, 1979
Clark DA, Philips FS, Steinberg SS, Barclay RK, Stock CC: Effects of N-methylformamide and related compounds in mouse sarcoma 180. Proc Soc Exp Biol and Med 84:203–207, 1953
Gescher A, Gibson NW, Hickman JA, Langdon SP, Ross D, Atassi G: N-methylformamide: antitumor activity and metabolism in mice. Br J Cancer 45:843–850, 1982
McVie JG, tenBokkel Huinink WW, Simonetti G, Dobbelman R: Phase I trial of N-methylformamide. Cancer Treat Rep 68:607–610, 1984
Ettinger DA, Orr DW, Rice AP, Donehower RC: Phase I trial of N-methylformamide in patients with advanced cancer. Cancer Treat Rep 69:489–493, 1985
O'Dwyer P, Donehower M, Sigman L, Fortner C, Aisner J, VanEcho DA: Phase I trial of N-methylformamide (NMF, NSC 3051). J of Clin Oncol 3:853–856, 1985
Spremulli EN, Dexter DL, Cummings FJ, Wiemann M, Salvatore J, Smith D, Matook G, Crabtree GW, Griffiths W, Calabresi P: Phase I clinical and pharmacological studies of monomethylformamide (N-MF). (Abstract) Proc Am Soc Clin Oncol 2:24, 1983
Forastiere AA, Young CW, Wittes RF: A Phase II trial of m-AMSA in Head and Neck Cancer. Cancer Chemother Pharmacol 6:145–146, 1981
Natale RB: Personal Communication
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vogel, W.C., Forastiere, A.A., Natale, R.B. et al. Phase II trial of N-methylformamide in advanced head and neck cancer. Invest New Drugs 5, 203–206 (1987). https://doi.org/10.1007/BF00203547
Issue Date:
DOI: https://doi.org/10.1007/BF00203547